ストックスクリーナーアプリを入手
0.46
9.79%
0.041
前日終値:
$0.419
開ける：
$0.4301
24時間の取引高:
321.69K
Relative Volume:
2.42
時価総額：
$10.33M
収益：
-
当期純損益:
$-58.52M
株価収益率:
-0.2201
EPS:
-2.09
ネットキャッシュフロー:
$-45.03M
1週間 パフォーマンス:
+27.35%
1か月 パフォーマンス:
-19.16%
6か月 パフォーマンス:
-66.91%
1年 パフォーマンス:
-64.34%
1日の値動き範囲:
$0.395
$0.499
1週間の範囲:
$0.3499
$0.499
52週間の値動き範囲:
$0.224
$1.8199
Nextcure Inc Stock (NXTC) Company Profile
名前
Nextcure Inc
セクター
電話
240-399-4900
住所
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
NXTC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
0.46 | 10.33M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-03-05 | アップグレード | Truist | Hold → Buy |
| 2021-01-15 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-07-16 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-07-13 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-13 | ダウングレード | SunTrust | Buy → Hold |
| 2020-06-01 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-03-24 | 開始されました | The Benchmark Company | Buy |
| 2020-03-02 | 開始されました | ROTH Capital | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-05 | 開始されました | Needham | Buy |
| 2019-11-26 | 開始されました | BTIG Research | Buy |
| 2019-07-09 | 開始されました | BofA/Merrill | Buy |
| 2019-06-03 | 開始されました | Morgan Stanley | Overweight |
| 2019-06-03 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Nextcure Inc (NXTC) 最新ニュース
Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks
NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia
NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan
CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India
NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia
NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India
ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC - Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa
NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia
NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World
2 Net Current Asset Value Stocks to Consider - GuruFocus.com
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN
NextCure Reports 2024 Financials and Strategic Progress - TipRanks
NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times
NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq
Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan
NextCure Inc. (NXTC) reports earnings - qz.com
Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com
NextCure stock plunges to 52-week low, hits $0.69 - MSN
NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada
Ventia Strengthens Leadership with New Company Secretary Appointment - MSN
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance
Eaton Vance Tax-Managed Diversified Equity Income Fund declares $0.0992 dividend - MSN
NextCure Faces Potential Delisting from Nasdaq Global Select Market Due to Minimum Bid Requirement Non-Compliance - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World
Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - Chosunbiz
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com
Nextcure Inc (NXTC) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):